# EDGAR Filing Document

**Accession Number:** 0001678660
**File Stem:** 0001193125-26-099442
**Filing Date:** 2026-3
**Character Count:** 21848
**Document Hash:** ea7673577c1cd3203b79781b03027f38
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-099442.hdr.sgml**: 20260310

**ACCESSION NUMBER**: 0001193125-26-099442

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 15

**FILED AS OF DATE**: 20260310

**DATE AS OF CHANGE**: 20260310

**EFFECTIVENESS DATE**: 20260310

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Prelude Therapeutics Inc
- **CENTRAL INDEX KEY:** 0001678660
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 811384762
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-294171
- **FILM NUMBER:** 26737362

**BUSINESS ADDRESS:**
- **STREET 1:** 175 INNOVATION BOULEVARD
- **CITY:** WILMINGTON
- **STATE:** DE
- **ZIP:** 19805
- **BUSINESS PHONE:** (302) 467-1280

**MAIL ADDRESS:**
- **STREET 1:** 175 INNOVATION BOULEVARD
- **CITY:** WILMINGTON
- **STATE:** DE
- **ZIP:** 19805

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Prelude Therapeutics Inc.
- **DATE OF NAME CHANGE:** 20160630

**As filed with the Securities and Exchange Commission on March 10, 2026**

**Registration No. 333-** 

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

________________

**FORM S-8**

**REGISTRATION STATEMENT** 

**UNDER THE** 

**SECURITIES ACT OF 1933**

________________

**PRELUDE THERAPEUTICS INCORPORATED**

(*Exact name of registrant as specified in its charter*)

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;**Delaware** |  | &nbsp;&nbsp;**81-1384762** |
| &nbsp;&nbsp;*(State or other jurisdiction of* |  | &nbsp;&nbsp;*(I.R.S. Employer* |
| &nbsp;&nbsp;*incorporation or organization)* |  | &nbsp;&nbsp;*Identification Number)* |
| &nbsp;&nbsp;**175 Innovation Boulevard** <br>**Wilmington, Delaware** |  | &nbsp;&nbsp;**19805** |
| &nbsp;&nbsp;*(Address of Principal Executive Offices)* |  | &nbsp;&nbsp;*(Zip Code)* |
|  | &nbsp;&nbsp;**2020 Equity Incentive Plan**<br>**2020 Employee Stock Purchase Plan**<br>|  |
|  | &nbsp;&nbsp;*(Full title of the plans)* |  |
|  | &nbsp;&nbsp;**Krishna Vaddi, Ph.D.**<br>**Chief Executive Officer** <br>**Prelude Therapeutics Incorporated**<br>**175 Innovation Boulevard** <br>**Wilmington, Delaware 19805**<br>|  |
|  | &nbsp;&nbsp;*(Name and address of agent for service)* |  |
|  | &nbsp;&nbsp;**(302) 467-1280**<br>|  |
|  | &nbsp;&nbsp;*(Telephone number, including area code, of agent for service)* |  |
|  | &nbsp;&nbsp;*Copies of correspondence to:*<br>Celia A. Soehner<br>Morgan, Lewis & Bockius LLP<br>One Oxford Centre, Thirty-Second Floor<br>Pittsburgh, PA 15219-6401<br>(412) 560-3300 |  |

---

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definition of "large accelerated filer", "accelerated filer", "smaller reporting company", and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☐ | Accelerated filer | ☐ |
| Non-accelerated filer | ☒  | Smaller reporting company | ☒ |
|  |  | Emerging growth company | ☐ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

------

**REGISTRATION OF ADDITIONAL SHARES**

**PURSUANT TO GENERAL INSTRUCTION E**

Prelude Therapeutics Incorporated (the "***Registrant***") is filing this Registration Statement with the Securities and Exchange Commission (the "***Commission***") to register the offer and sale of (a) 3,147,681 additional shares of the Registrant's common stock, par value $0.0001 per share (the "***Common Stock***") available for issuance under the Registrant's 2020 Equity Incentive Plan ("***2020 EIP***"), pursuant to the provision of the 2020 EIP providing for an annual 5% automatic increase in the number of shares reserved for issuance and (b) 629,536 additional shares of Common Stock available for issuance under the Registrant's 2020 Employee Stock Purchase Plan ("***2020 ESPP***"), pursuant to the provision of the 2020 ESPP providing for an annual 1% automatic increase in the number of shares reserved for issuance.

In accordance with General Instruction E of Form S-8, and only with respect to the Common Stock issuable under the 2020 EIP and 2020 ESPP, this Registration Statement hereby incorporates by reference the contents of the Registrant's Registration Statement on Form S-8 filed with the Commission on September 25, 2020 (Registration No. 333-249032), March 16, 2021 (Registration No. 333-254349), March 17, 2022 (Registration No. 333-263642), March 15, 2023 (File No. 333-270549), February 16, 2024 (File No. 333-277122), and March 10, 2025 (File No. 333-285662) to the extent not superseded hereby.

**PART II**

**INFORMATION REQUIRED IN THE REGISTRATION STATEMENT**

**Item 3. Incorporation of Documents by Reference.**

The following documents filed by the Registrant with the Commission pursuant to the Securities Exchange Act of 1934, as amended (the "***Exchange Act***") are incorporated herein by reference:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) the Registrant's Annual Report on [<u>Form 10-K</u>](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001678660/000119312526099428/prld-20251231.htm) for the year ended December 31, 2025, filed with the Commission on March 10, 2026;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) our Current Reports on Form 8-K, filed with the Commission on [<u>January 9, 2026</u>](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001678660/000119312526008280/prld-20260109.htm) and [<u>February 3, 2026</u>](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001678660/000119312526034564/prld-20260129.htm); and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) the description of the Common Stock contained in the Registrant's registration statement on [<u>Form 8-A</u>](https://www.sec.gov/Archives/edgar/data/1678660/000119312520246935/d899345d8a12b.htm) (File No. 001-39527) filed on September 16, 2020 under Section 12(b) of the Exchange Act, including any amendment or report filed for the purpose of updating such description, including [<u>Exhibit 4.5</u>](https://www.sec.gov/Archives/edgar/data/1678660/000095017024016016/prld-ex4_5.htm) of the Registrant's Annual Report on Form 10-K for the year ended December 31, 2023, filed with the Commission on February 15, 2024 (File No. 001-39527).

All documents subsequently filed by the Registrant pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act subsequent to the filing of this Registration Statement and prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the date of filing such documents, except that information furnished to the Commission under Item 2.02 or Item 7.01 in Current Reports on Form 8-K and any exhibit relating to such information, shall not be deemed to be incorporated by reference in this Registration Statement. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained in any subsequently filed document which also is deemed to be incorporated by reference herein modifies or supersedes such statement.

------

**Item 8. Exhibits.**

The following exhibits are filed herewith:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **Exhibit** |  | **Incorporated by Reference** | **Incorporated by Reference** | **Incorporated by Reference** | **Incorporated by Reference** | **Filed** |
| **<u>Number</u>** | **<u>Exhibit Description</u>** | **<u>Form</u>** | **<u>File No.</u>** | **<u>Exhibit</u>** | **<u>Filing Date</u>** | **<u>Herewith</u>** |
| 5.1 | [<u>Opinion of Morgan, Lewis & Bockius LLP</u>](prld-ex5_1.htm) |  |  |  |  | X |
| 23.1 | [<u>Consent of Morgan, Lewis & Bockius LLP (contained in Exhibit 5.1</u>](prld-ex5_1.htm)) |  |  |  |  | X |
| 23.2 | [<u>Consent of Ernst & Young LLP, Independent Registered Public Accounting Firm</u>](prld-ex23_2.htm) |  |  |  |  | X |
| 24.1 | [<u>Power of Attorney (included on the signature page to this Registration Statement)</u>](#poa) |  |  |  |  | X |
| 99.1 | [<u>2020 Equity Incentive Plan and forms of award agreements thereunder</u>](https://www.sec.gov/Archives/edgar/data/0001678660/000119312520249549/d935180dex103.htm) | S-1/A | 333-248628 | 10.3 | 9/21/2020 |  |
| 99.2 | [<u>2020 Employee Stock Purchase Plan and forms of award agreements thereunder</u>](https://www.sec.gov/Archives/edgar/data/0001678660/000119312520249549/d935180dex104.htm) | S-1/A | 333-248628 | 10.4 | 9/21/2020  |  |
| 107 | [<u>Filing Fee Table</u>](prld-exfiling_fees.htm) |  |  |  |  | X |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Wilmington, State of Delaware, on this 10th day of March, 2026.

**PRELUDE THERAPEUTICS INCORPORATED**

---

| | |
|:---|:---|
| &nbsp;&nbsp;By: | &nbsp;&nbsp;*/s/ Krishna Vaddi* |
|  | &nbsp;&nbsp;Krishna Vaddi |
|  | &nbsp;&nbsp;Chief Executive Officer |

---

**POWER OF ATTORNEY**

**KNOW ALL PERSONS BY THESE PRESENTS**, that each person whose signature appears below hereby constitutes and appoints Krishna Vaddi and Bryant Lim, and each of them, as his or her true and lawful attorney-in-fact and agent with full power of substitution, for him or her in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his or her substitute, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities and on the date indicated.

---

| | | |
|:---|:---|:---|
| **Name** | **Title** | **Date** |
| */s/ Krishna Vaddi*<br>Krishna Vaddi, Ph.D.  | Chief Executive Officer and Director<br>(Principal Executive Officer) | March 10, 2026 |
| */s/ Bryant Lim*<br>Bryant Lim | Chief Financial Officer<br>(Principal Financial and Accounting Officer) | March 10, 2026 |
| */s/ Paul A. Friedman*<br>Paul A. Friedman, M.D. | Director | March 10, 2026 |
| */s/ Martin Babler*<br>Martin Babler  | Director | March 10, 2026 |
| */s/ Paul Scherer*<br>Paul Scherer, M.D. | Director | March 10, 2026 |
| */s/ David Bonita*<br>David Bonita, M.D. | Director | March 10, 2026 |
| */s/ Katina Dorton*<br>Katina Dorton<br>| Director | March 10, 2026 |
| */s/ Victor Sandor* <br>Victor Sandor, M.D.C.M.  | Director | March 10, 2026 |

---

------

## Exhibit 5.1

![img162401780_0.gif](img162401780_0.gif)

**EXHIBIT 5.1**

March 10, 2026

Prelude Therapeutics Incorporated<br>175 Innovation Boulevard<br>Wilmington, Delaware 19805

Re: <u>Prelude Therapeutics Incorporated</u> 

<u>Registration Statement on Form S-8 Filed on March 10, 2026</u>

Ladies and Gentlemen:

We have acted as counsel to Prelude Therapeutics Incorporated, a Delaware corporation (the "***Company***"), in connection with its filing of the referenced Registration Statement on Form S-8 (the "***Registration Statement***") under the Securities Act of 1933, as amended (the "***Act***"), with the Securities and Exchange Commission (the "***SEC***") on the date hereof. The Registration Statement relates to the registration under the Act of an aggregate 3,777,217 shares (the "***Shares***") of the Company's Common Stock, $0.0001 par value per share (the "***Common Stock***"), consisting of (i) 3,147,681 shares of Common Stock subject to issuance by the Company upon exercise or settlement of awards granted or to be granted under the Company's 2020 Equity Incentive Plan (the "***2020 EIP***") and (ii) 629,536 shares of Common Stock subject to issuance by the Company pursuant to purchase rights to acquire shares of Common Stock granted or to be granted under the Company's 2020 Employee Stock Purchase Plan (the "***ESPP***" and, together with the 2020 EIP, the "***Plans***").

In connection with this opinion letter, we have examined the Registration Statement and originals, or copies certified or otherwise identified to our satisfaction, of (i) the Company's Amended and Restated Certificate of Incorporation, (ii) the Company's Amended and Restated Bylaws, (iii) the Plans, and (v) such other documents, records and other instruments as we have deemed appropriate for the purposes of the opinions set forth herein.

We have assumed the genuineness of all signatures, the legal capacity of all natural persons, the authenticity of the documents submitted to us as originals, the conformity with the originals of all documents submitted to us as certified, electronic or photostatic copies and the authenticity of the originals of all documents submitted to us as copies. With respect to matters of fact relevant to our opinions as set forth below, we have relied upon certificates of officers of the Company, representations made by the Company in documents examined by us, and representations of officers of the Company.

Based upon the foregoing, we are of the opinion, as of the date hereof, that the Shares have been duly authorized by the Company and, when issued and delivered by the Company in the manner and on the terms described in the Plans, will be validly issued, fully paid, and non-assessable.

The opinions expressed herein are limited to the General Corporation Law of the State of Delaware.

------

We hereby consent to the use of this opinion as Exhibit 5.1 to the Registration Statement. In giving such consent, we do not hereby admit that we are acting within the category of persons whose consent is required under Section 7 of the Act or the rules or regulations of the SEC thereunder.

Very truly yours,

/s/ Morgan, Lewis & Bockius LLP

------

## Exhibit 23.2

Exhibit 23.2

**Consent of Independent Registered Public Accounting Firm**

We consent to the incorporation by reference in the Registration Statement (Form S-8) pertaining to the 2020 Equity Incentive Plan and to the 2020 Employee Stock Purchase Plan of Prelude Therapeutics Incorporated of our report dated March 10, 2026, with respect to the financial statements of Prelude Therapeutics Incorporated included in its Annual Report (Form 10-K) for the year ended December 31, 2025, filed with the Securities and Exchange Commission.

/s/ Ernst & Young LLP

Philadelphia, Pennsylvania

March 10, 2026

------

## Ex-Filing

?xml version='1.0' encoding='ASCII'? EX-FILING FEES

---

| |
|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Calculation of Filing Fee Tables**  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **S-8**  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Prelude Therapeutics Inc**  |

---

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Security Type**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Security Class Title**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Fee Calculation Rule**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Amount Registered**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Proposed Maximum Offering Price Per Unit**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Maximum Aggregate Offering Price**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Fee Rate**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Amount of Registration Fee**  |
| 1 | Equity | Common stock, par value $0.0001 per share | Other | 3147681 | $2.65 | $8341354.65 | 0.0001381 | $1151.94 |
| 2 | Equity | Common stock, par value $0.0001 per share | Other | 629536 | $2.25 | $1416456.00 | 0.0001381 | $195.61 |
| Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: |  | $9757810.65  |  | $1347.55  |
| Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  |  |  |  | $0.00  |
| Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  |  |  |  | $1347.55  |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Offering Note** <br>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <sup>1</sup> Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the "Securities Act"), this Registration Statement shall also cover any additional shares of the Registrant's common stock, par value $0.0001 per share ("Common Stock") that becomes issuable pursuant to the provisions of the Registrant's 2020 Equity Incentive Plan ("2020 EIP") and 2020 Employee Stock Purchase Plan ("2020 ESPP") by reason of any stock dividend, stock split, recapitalization or other similar transaction effected without the Registrant's receipt of consideration that results in an increase in the number of the Registrant's outstanding shares of Common Stock. The amount registered represents additional shares of Common Stock to be registered and available for grant under the 2020 EIP resulting from the annual 5% automatic increase in the number of authorized shares available for issuance under the 2020 EIP. The Proposed Maximum Offering Price Per Unit is estimated in accordance with Rules 457(c) and 457(h) of the Securities Act solely for the purpose of calculating the registration fee. The proposed maximum offering price per share of $2.65 was computed by averaging the high and low prices of a share of Common Stock as reported on The Nasdaq Stock Market LLC ("Nasdaq") on March 3, 2026.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <sup>2</sup> The amount registered represents additional shares to be registered and available for grant under the 2020 ESPP resulting from the annual 1% automatic increase in the number of authorized shares available for issuance under the 2020 ESPP. The Proposed Maximum Offering Price Per Unit is estimated in accordance with Rules 457(c) and 457(h) of the Securities Act solely for the purpose of calculating the registration fee. The proposed maximum offering price per share of $2.25 was computed by averaging the high and low prices of a share of Common Stock as reported on Nasdaq on March 3, 2026, multiplied by 85%, which is the percentage of the trading price per share applicable to purchasers under the 2020 ESPP.

---

| | |
|:---|:---|
| | |
| **Rule 457(p)** | **Rule 457(p)** |
| Fee Offset Claims | N/A |
| Fee Offset Sources | N/A |

---